The Global Medical Device Podcast, powered by Greenlight Guru, is where today's brightest minds in the medical device industry go to get their most useful and actionable insider knowledge, direct from some of the world's leading medical device experts and companies.
Listen to episodes
60 recent
September 21, 2026Episode 47433 min
#474: Behind the QMSR Audits: The Top 5 FDA Citations & Risk Management Pitfalls
In this episode of the Global Medical Device Podcast, host Etienne Nichols sits down with Nikhil Mangale, Vice President of Quality at Kapstone Medical, to discuss the real-world impact of the FDA's Quality Management System Regulation (QMSR). Seven months post-implementation, the industry is seeing actual inspection data that shifts the focus away from superficial documentation updates and directly onto core quality system operations. Nikhil breaks down the top five areas where the FDA is issuing citations under the new regulation: risk management, supplier controls, complaint handling, Unique Device Identification (UDI), and corrective actions. The discussion highlights how the industry spent years worrying about renaming documents like Design History Files (DHFs) to Design and Development Files (DDFs), yet inspectors are bypassing mere translation projects to evaluate how information flows across living quality processes. The conversation offers actionable guidance on conducting thorough, multi-layered gap assessments for both active and legacy products. Nikhil provides strategic advice for small companies and startups on prioritizing risk management, handling supplier audit visibility, navigating ISO 13485 alignment, and weighing the benefits of participating in programs like MDSAP. Takeaways Prioritize Risk as a Living Process: Risk management must continuously integrate post-market feedback, complaint data, and nonconformances rather than remaining a static file archived after design release. Re-evaluate Supplier Audits for External Scrutiny: Routine supplier audit records are now accessible to FDA inspectors; ensure reports are well-documented, audit schedules are risk-proportionate, and findings are formally resolved. Implement a Three-Layer Mapping Strategy: Move beyond surface-level terminology updates (Layer 1) to establish subclause conformity (Layer 2) and verify operational evidence across interrelated processes (Layer 3). Maintain Open Design and Development Files (DDF): Unlike legacy DHFs that were closed at commercial launch, DDFs must remain active throughout the product lifecycle to evaluate ongoing design changes. Formulate a Defensible Quality Plan: When addressing gaps, document a risk-prioritized, sequential quality plan to show objective evidence of a structured compliance roadmap during an inspection. References FDA Compliance Program CP 7382.045: The FDA inspection guidance replacing QSIT, organizing surveillance around core QMS areas and specific regulations. ISO 13485:2016: The international standard for medical device quality management systems incorporated by reference into the FDA's QMSR. Etienne Nichols LinkedIn Profile - Connect with the host of the Global Medical Device Podcast. Feedback Call-to-Action We want to hear from you! What challenges are you experiencing with your QMSR implementation or risk management files? Send your feedback, reviews, or topic suggestions directly to podcast@greenlight.guru . We personally review and respond to every message from our listeners! Sponsors This episode is brought to you by Greenlight Guru .
September 21, 2026Episode 47342 min
#473: The MedTech Odyssey: Bridging Academic Science to Series A Success
The transition from academic research to commercial MedTech entrepreneurship requires a strategic mindset shift, particularly when navigating high-risk vascular innovations. Jordi Martorell, CEO and co-founder of Aortyx, shares his journey from mapping arterial blood flow at the Harvard-MIT Biomedical Engineering Center to developing bioresorbable endovascular patches for aortic dissection. Driven by a desire to solve true unmet medical needs, Martorell leveraged his background in fluid mechanics and vascular engineering to build a company capable of transforming clinical outcomes. Navigating early-stage funding outside major venture capital hubs presents unique structural challenges. Martorell explains how Aortyx sustained a multi-year development timeline prior to Series A by combining friends-and-family rounds, community equity crowdfunding, and non-dilutive European public grants. Maintaining radical transparency regarding investment risk and establishing clean cap table structures were critical components in maintaining investor trust over extended timelines. Securing a Series A round for a Class III medical device requires managing shifting macroeconomic landscapes, rising clinical costs, and complex regulatory pathways. Martorell reflects on the realities of negotiating with venture capital firms, facing unexpected round restructurings, and adapting to post-pandemic inflation across preclinical and clinical trial execution. The discussion highlights the importance of maintaining core product continuity while remaining flexible in execution strategy. Takeaways Validate Unmet Needs Over Market Incrementalism: Avoid competing in saturated markets where large strategics only seek non-inferiority; focus R&D on clear, unaddressed clinical gaps. Structure Clean Cap Tables for Retail Capital: When utilizing equity crowdfunding or large groups of early individual investors, leverage syndication and SPVs to preserve a single point of negotiation for future institutional VCs. Prepare for Extended Series A Timelines: Deep-tech Class III devices can face multi-year fundraising cycles, requiring a multi-tiered capital strategy blending non-dilutive grants, bridge rounds, and follow-on commitments. Factor Post-Pandemic Inflation into Preclinical Budgets: Account for significant cost increases in animal studies, raw material procurement, and clinical trial execution compared to historical baseline estimates. References Aortyx: Medical device company developing bioresorbable endovascular patches for aortic dissection repair. EIC Accelerator Program: European Innovation Council grant initiative providing non-dilutive funding to high-impact European startups. Capital Cell: Specialized health-focused equity crowdfunding platform based in Spain. Etienne Nichols: LinkedIn Profile Feedback Call-to-Action We want to hear from you. What were your key takeaways from this episode? Do you have topics or guest suggestions for future discussions? Send your thoughts, feedback, and questions directly to podcast@greenlight.guru . Every email is reviewed by our team to help shape upcoming episodes. Sponsors This episode is brought to you by Greenlight Guru. Learn how Greenlight Guru's modern QMS and EDC software can support your medical device journey at greenlight.guru .
September 21, 2026Episode 47240 min
#472: Cost Containment: Right-Sizing Medical Device Cybersecurity with Chris Gates
Medical device cybersecurity is no longer an optional feature or a last-minute checkbox prior to market entry. Hosted by Etienne Nichols, this episode features Chris Gates, founder and CEO of arsMedSecurity, who delivers a practical, engineering-first perspective on embedding security directly into the development lifecycle. Gates highlights that deferring cybersecurity efforts until the end of development leads to severe financial penalties, extended regulatory delays, and potential company failure. The discussion demystifies common misconceptions held by executive teams and "bean counters," such as the myth that off-network devices or small companies are exempt from cyber threats. Under current FDA expectations and the eStar submission process, any medical device containing software is subject to stringent pre-market cybersecurity requirements. Gates illustrates how unexpected 180-day regulatory holds impact a company's daily burn rate, showing that proactive security measures are far cheaper than reactive fixes. Looking ahead, the conversation explores the evolving threat landscape driven by Large Language Models (LLMs) and advanced exploits that reduce vulnerability exploitation windows from years to minutes. Gates provides concrete steps for medical device manufacturers to take control of their product security, emphasizing early threat modeling, continuous risk management, and the alignment of software development SOPs with recognized international standards. Takeaways Calculate Delay Impact via Burn Rate: Evaluate cybersecurity risk against your organization's daily burn rate multiplied by a potential 180-day FDA submission delay to understand the true financial cost of non-compliance. Software Triggers Cyber Requirements: Do not assume a device is exempt from cybersecurity requirements because it lacks active internet connectivity; any device running software falls under FDA pre-market expectations. Perform Threat Modeling Before Hardware Freeze: Execute system-level threat modeling (e.g., STRIDE methodology) during the initial design phase before finalizing active hardware components and component selections. Adopt Recognized SDLC Standards: Establish standard operating procedures (SOPs) that map secure development activities directly to ISO/IEC 81001-5-1 and ISO 62304 frameworks. References Medical Device Cybersecurity for Engineers and Manufacturers (2nd Edition): Practical reference handbook authored by Chris Gates detailing implementation techniques for device developers. ISO/IEC 81001-5-1: Health software and health IT systems safety, effectiveness, and security standard for secure development lifecycles. STRIDE Threat Model: A system decomposition methodology developed by Microsoft to identify data-in-motion and data-at-rest security threats per system element. Host LinkedIn Profile: Connect with Etienne Nichols on LinkedIn . Feedback Call-to-Action We want to hear from you! What cybersecurity challenges is your team currently navigating during product development? Send your questions, feedback, or topic suggestions directly to us at podcast@greenlight.guru . Every email is reviewed by our team, and we regularly incorporate listener-submitted questions into upcoming episodes and expert Q&A segments. Sponsors This episode is brought to you by Greenlight Guru .
September 21, 2026Episode 47138 min
#471: From AI Visuals to FDA Approval: Fixing MedTech’s Design-to-Market Gap
Many MedTech startups and innovators focus heavily on core technology development, often assuming physical product design is simple polishing once a working concept exists. Michael Sprauve explains that this approach frequently creates a gap between brilliant engineering and a market-ready, commercially viable medical device. Succeeding in hardware requires looking past the technology to consider every individual who will interact with the device throughout its entire lifecycle. A critical challenge in MedTech design is managing the complex web of user personas involved. Unlike consumer electronics, where design caters to one or two primary end users, medical devices must meet the needs of surgeons, operating room staff, post-surgical nurses, maintenance technicians, disposal personnel, and regulatory bodies. Overlooking support staff—such as nurses managing crowded, alarm-fatigued rooms or technicians handling biological waste and lithium-ion batteries—can derail an otherwise promising device. As AI image generation tools become widespread, creators increasingly present AI-rendered concepts as finished designs. While these tools offer creative inspiration, they lack awareness of physical constraints, manufacturing rules, and real-world usability. By establishing a non-physical "North Star" based on emotional attributes and sensory cues, design teams can guide products through concepting, engineering, and manufacturing without losing sight of user needs and regulatory mandates. Takeaways Map the Entire User Lifecycle: Design for every individual who touches the product, from the operating surgeon to the maintenance nurse, sterilization technician, and waste handler. Mitigate Alarm Fatigue Early: Ensure auditory and visual indicators comply with FDA standards while avoiding chaotic, high-stress clinical environments caused by competing alerts. Establish a Non-Physical North Star: Use emotional and sensory attributes to anchor design, engineering, and CMF (Color, Material, Finish) choices, keeping the project aligned across development stages. Involve Manufacturing Engineers from Day One: Incorporate Design for Manufacturability (DFM) considerations during initial concept phases rather than waiting until design freeze to prevent expensive re-tooling and regulatory delays. References Speck Design: Hardware design and engineering firm specializing in taking complex medical and life science concepts to market. Intuitive Surgical (DaVinci & Ion Platforms): Advanced robotic-assisted surgical systems highlighting high-precision hardware requirements discussed in the episode. Microport MedBot (Toumai System): Four-arm laparoscopic surgical robot referenced as a key benchmark for international regulatory clearances. Etienne Nichols' LinkedIn: Etienne Nichols on LinkedIn Feedback Call-to-Action We want to hear from you! What challenges have you faced when balancing user feedback against clinical and regulatory requirements? Send your thoughts, topic suggestions, or questions to podcast@greenlight.guru . Every email goes directly to our team, and we personally review listener notes for future episodes. Sponsors This episode is brought to you by Greenlight Guru . Learn more at greenlight.guru .
September 22, 2026Episode 47039 min
#470: The Real Cost of MedTech Innovation: From Idea to Pre-Production with Lisa Voronkova
Building a medical device rarely follows the smooth, predictable trajectory presented in investor pitch decks. While regulatory consultants often default to "it depends," medical device teams require concrete figures regarding engineering hours, calendar timelines, and budget allocations to bring a concept to market safely and effectively. Lisa Voronkova, co-founder of OVA Solutions, draws on a dataset from developing over 200 medical devices to pull back the curtain on hardware engineering realities. She outlines the four structured phases of engineering—Discovery, Proof of Concept, Design, and Development—explaining how disciplined phase-gate management mitigates costly late-stage redesigns and protects capital. The conversation dives into transparent, real-world case studies ranging from short pre-production hardware tracks to complex, multi-year continuous glucose monitor (CGM) developments. Lisa and host Etienne Nichols explore the true financial scope of Design for Manufacturability (DFM), realistic blended hourly rates across global markets, and why shortcuts in early contextual validation often lead to catastrophic manufacturing overhead. Takeaways Phase-Gate Discipline Controls Financial Risk: Moving into high-cost tooling or manufacturing before proving core function in a low-fidelity mock-up risks turning a $1,500 prototype adjustment into a $150,000 production mold tool rework. Validate in the Real Operating Environment: Conducting customer interviews is insufficient if engineers do not observe the actual clinical setting; lighting conditions, sterile field constraints, and physical workflows dictate foundational hardware requirements. Benchmark Engineering Hours accurately: Standard hardware projects generally fall into three tiers: 2,000–3,000 hours for simple electronics integrations, 5,000–6,000 hours for multi-system electro-mechanical devices, and 10,000–30,000+ hours for high-complexity Class II/III systems (e.g., CGMs, surgical robotics). DFM Accounts for a Massive Secondary Investment: Completing the initial "golden sample" prototype is only half the engineering journey; preparing a device for mass production (assembly sequences, test fixtures, second-sourcing components) can demand an additional 2,500 to 7,000+ engineering hours. References OVA Solutions: Engineering group specializing in full-cycle medical device design, electronics, and firmware development. The Hardware Bible: Book authored by Lisa Voronkova detailing practical expectations and framework strategies for medical device development. Host LinkedIn: Connect with Etienne Nichols on LinkedIn for ongoing discussions with MedTech industry leaders. Feedback Call-to-Action We want to hear from you! What was your biggest takeaway regarding medical device engineering budgets and timelines? Have a guest recommendation or a topic you want us to dissect in an upcoming episode? Send your feedback, reviews, and topic suggestions directly to podcast@greenlight.guru . Etienne reads every message and responds personally to our listeners! Sponsors This episode is brought to you by Greenlight Guru . Learn more at www.greenlight.guru .
September 21, 2026Episode 46939 min
#469: Why Market Strategy Comes First in MedTech Development
Medical device startups frequently fall into the trap of developing complex technology first, only to struggle downstream with clinical adoption, regulatory hurdles, and reimbursement. In this episode, host Etienne Nichols sits down with Shai Policker, Managing Partner at Edge Medical Ventures, to explore why reversing this traditional paradigm leads to sustainable, category-defining products. Policker details how working backward from validated clinical needs—identified directly by multinational corporations, physicians, and health systems—allows developers to map out the regulatory and reimbursement landscapes before building the first prototype. By addressing the commercial critical chain early, ventures avoid costly mid-development pivots and align technical innovation with true market demand. The conversation covers real-world portfolio examples, including non-invasive urodynamics and smart surgical drains, demonstrating how focused differentiation transforms clinical workflows and patient outcomes. Policker also shares key insights into helping international MedTech companies navigate the nuances of the US healthcare system. Takeaways Validate Reimbursement Before Prototyping: Map existing CPT/HCPCS codes, coverage policies, and economic incentives prior to freezing design specifications. Leverage Strategic Partnerships Early: Engage R&D, sales, and clinical leaders at strategic corporations to identify validated gaps in three-to-five-year commercial pipelines. Target Dramatic Outcome Improvements: Focus engineering efforts on innovations that yield step-function clinical improvements rather than incremental 5% gains. Preserve Familiarity for Pathways: Design physical devices to deliver game-changing outcomes while maintaining predicate-equivalent forms to fit existing 510(k) cleared classes and billing mechanisms. Evaluate the Full Critical Chain: Ensure every element—referral patterns, physician time, hospital economics, regulatory constraints, and patient compliance—is fully solved before committing venture capital. Essential References Edge Medical Ventures : Venture creation firm focused on category-defining medical device companies built around validated strategic needs. Etienne Nichols LinkedIn : Connect with podcast host and MedTech community leader Etienne Nichols. Feedback & Community We want to hear from you! What was your biggest takeaway from Shai Policker's approach to venture creation? Do you have topic suggestions or guests you would like to see on the show? Send your thoughts, feedback, and questions directly to the team at podcast@greenlight.guru . Every email receives a personalized response from our team! Episode Sponsors This episode is brought to you by Greenlight Guru , the only MedTech lifecycle management platform purpose-built for medical device companies. Learn how to accelerate your medical device journey at www.greenlight.guru .
September 26, 2024Episode 38444 min
#384: Insights from an Ex-FDA Investigator: Compliance, Quality Systems, and MedTech Trends
In this episode of the Global Medical Device Podcast , host Etienne Nichols sits down with Vincent Cafiso, Director of Quality and Regulatory Services at Creo Consulting and former FDA investigator. Vincent brings 30 years of life sciences and regulatory expertise, offering a unique perspective on navigating FDA inspections, building robust quality systems, and managing innovation within the MedTech industry. They dive deep into the challenges faced by MedTech companies, particularly small startups, and how to balance regulatory requirements with creativity and innovation. Vincent also highlights the common pitfalls companies encounter with design controls and shares strategies to ensure R&D and production teams work in harmony. Key Timestamps: [00:01] – Introduction : Vincent Cafiso’s background as an FDA investigator and transition into industry. [04:15] – Crayo Consulting’s Scope : How Creo Consulting supports MedTech companies from launch strategy to compliance. [12:40] – Bridging R&D and Production : Overcoming challenges when R&D environments don’t align with production standards. [19:50] – Top Trends in Quality Systems : Addressing documentation gaps and missing standards in design history files. [27:10] – Management’s Role in Supporting Quality : The importance of management’s involvement in enforcing quality controls and processes. [38:30] – From FDA to Industry : How Vincent’s FDA background influences his approach to quality and compliance. [54:25] – Skip-Level Meetings and Breaking Silos : Enhancing collaboration and communication within large organizations. [1:06:00] – Final Takeaways and Advice : Building a culture of quality and fostering innovation while staying compliant. Key Quotes: “The regulations are written for tongue depressors and pacemakers—two very different devices. It’s up to the companies to interpret how to apply those rules to their specific products.” – Vincent Cafiso “Documentation shouldn’t just be a checkbox for submission. There’s a lot more innovation happening that doesn’t make it onto paper because companies don’t realize its value.” – Vincent Cafiso Key Takeaways: 1. MedTech Trends: Alignment of R&D and Production : Ensure that testing environments and protocols in R&D align with the standards of production to avoid costly discrepancies and rework. Regulatory Understanding Across Teams : Companies need to educate teams on the specific regulatory standards that apply to their product types to avoid misinterpretation and gaps in compliance. Cross-Departmental Collaboration : Maintaining a startup-like collaborative culture, even as the company scales, is crucial for innovation and quality. 2. Practical Tips for MedTech Professionals: Integrate Quality Early : Implement quality controls and validation processes at the R&D stage to avoid repeating tests or redesigns during production. Leverage Skip-Level Meetings : Encourage direct communication between upper management and employees for better understanding and faster issue resolution. Document Everything : Don’t treat documentation as a formality. Capture all the engineering studies and real data to support design decisions and regulatory submissions. 3. Questions for Future Consideration: How can large organizations maintain the flexibility and collaborative spirit of a startup? What creative approaches can be used to align R&D and production standards in smaller companies? What role will emerging technologies like AI and IoT play in shaping future regulatory landscapes? References: Vincent Cafiso on LinkedIn Etienne Nichols on LinkedIn Creo Consulting : Vincent Cafiso’s current company offering regulatory and quality services to MedTech organizations. FDA Guidance on Design Controls : Essential reading for understanding how to document and verify design history files. Greenlight Guru's EQMS Software : A quality management system built specifically for the MedTech industry, aiding in compliance and product development. Connect with Etienne Nichols on LinkedIn . MedTech 101: What is FDA Inspection Readiness? FDA inspection readiness refers to the ongoing state of compliance and preparedness for an FDA audit or inspection. It involves having robust quality systems, complete documentation, and trained personnel to demonstrate adherence to applicable regulations and standards. This ensures that a company can efficiently respond to any FDA inquiries and avoid costly delays or compliance issues. What are Design Controls? Design controls are a set of quality practices and procedures integrated into the product development process to ensure that medical devices meet user needs, intended uses, and specified requirements. They include stages like design planning, design inputs and outputs, verification, validation, and design transfer. Poll for the Audience: What is the biggest challenge your MedTech company faces when preparing for FDA inspections? a) Documentation and record-keeping b) Cross-departmental communication c) R&D and production alignment d) Understanding complex regulations Share your answer and thoughts by emailing us at podcast@greenlight.guru ! Feedback: Did you enjoy this episode? Leave us a review on iTunes and share your thoughts! Your feedback helps us improve and curate content that matters most to you. Feel free to email us at podcast@greenlight.guru with any suggestions for future topics or guest recommendations. Sponsor Segment: This episode is brought to you by Greenlight Guru , the only quality management software designed by MedTech professionals for MedTech companies. With a robust EQMS platform, Greenlight Guru helps streamline compliance and innovation processes, ensuring faster market access and safer medical devices. Visit greenlight.guru to learn more and schedule a demo today!
July 27, 2026Episode 46631 min
#466: Leaving the Ivory Tower - How Notified Body Engagement Unlocks Startup Growth
Many early-stage medical device founders face a major dilemma: how do you prove regulatory maturity to investors and partners before you actually hold a final CE mark or FDA approval? Waiting until the end of a long development cycle creates significant commercial risk. By treating regulatory readiness as a continuous maturity process rather than an all-or-nothing milestone, startups can build trust early and avoid costly late-stage surprises. In this episode, host Etienne Nichols sits down with Malte Knowles Schmidt, Global Portfolio Lead for Medical Device Software, AI, and Cybersecurity at TÜV SÜD. Drawing from his background as an ICU nurse, an R&D product leader for Class III cardiac implantables at Biotronik, and now a notified body leader, Malte breaks down how startups can step out of their silos. He emphasizes that notified bodies and medical device companies must both "leave the ivory tower" to establish practical, real-world communication long before a formal audit occurs. The conversation explores concrete strategies for demonstrating regulatory maturity during development, including standing up an enterprise Quality Management System (eQMS), securing partial ISO 13485 certification for core design processes, and leveraging external testing as strategic "breadcrumbs." Malte also cautions founders against chasing "Pyrrhic certifications"—winning regulatory approval at the cost of commercial viability—and shares practical guidance on when and how to initiate early structured dialogues with notified bodies. Key Timestamps 00:00 - 02:15 | Introduction to the "Regulatory Ivory Tower" Etienne introduces guest Malte Knowles Schmidt and sets up the challenge of proving regulatory maturity early in the startup lifecycle. 02:16 - 05:04 | Why Communication Gap Exists Between Startups & Notified Bodies Malte discusses why structured dialogues often feel too abstract for founders and why concrete examples are needed to make early engagement approachable. 05:05 - 08:30 | Defining Regulatory Maturity & The Agile QMS Exploring how investors view regulatory progress, why build-measure-learn mindsets belong inside a QMS, and how an eQMS acts as a foundational framework. 08:31 - 12:10 | Unlocking Value Through Partial ISO 13485 Certification A breakdown of how certifying core design and development processes early builds commercial credibility and attracts investor funding before full scope audits. 12:11 - 16:45 | Leveraging External Testing & Avoiding "Pyrrhic Certifications" How penetration testing and biocompatibility act as evidence breadcrumbs, plus the trap of sacrificing commercial viability just to get a certificate. 16:46 - 20:30 | When and How to Initiate Contact with a Notified Body Practical advice for founders on overcoming the fear of reaching out, preparing essential homework (intended purpose, risk classification), and taking the first step. Quotes "A Pyrrhic certification comes from a Pyrrhic victory, where you win the battle, but the losses are so great that the victory is basically meaningless... startups make the certification their core goal and not the commercial success." - Malte Knowles Schmidt "If you're asking yourself the question, 'Should I be talking to a notified body?'—then stop right there, because the answer is yes." - Malte Knowles Schmidt Key Takeaways Establish Early Regulatory Breadcrumbs: Investors want to see continuous progression. Utilizing an eQMS, conducting third-party testing (e.g., penetration or biocompatibility testing), and mapping regulatory roadmaps provide tangible proof of maturity long before final approval. Consider Partial ISO 13485 Certification: Startups do not need to wait for full scope certification. Certifying core design and development processes first demonstrates organizational discipline and can unlock major funding rounds. Avoid the Pyrrhic Certification Trap: Do not sacrifice your core business model or reduce critical product capabilities solely to make certification easier. Always align regulatory strategy with ultimate commercial viability. Treat Your QMS as an Agile System: Quality management is not a static set of restrictive rules; it is an iterative framework that should evolve alongside your product and team processes. Initiate Dialogue Early: Notified bodies are accessible for preliminary discussions. Reaching out early helps validate your intended purpose, risk classification, and submission assumptions before sinking capital into the wrong pathway. References White Paper: Leaving the Regulatory Ivory Tower: How Early Notified Body Dialogues Reduce Business Risk by Malte Knowles Schmidt (TÜV SÜD). ISO 13485 Standard: Quality management systems requirements for regulatory purposes in the medical device sector. Host LinkedIn: Etienne Nichols on LinkedIn MedTech 101 Section Pyrrhic Certification: Named after King Pyrrhus of Epirus, whose army won a battle against the Romans but suffered devastating losses in the process. In MedTech, a Pyrrhic certification occurs when a company successfully gets a medical device certified, but had to compromise so many features, intended uses, or commercial claims during the process that the resulting product has no real value in the market. Notified Body: An independent organization designated by an EU member state to assess whether a medical device complies with applicable regulatory standards (such as EU MDR) before it can be placed on the European market. Think of them as accredited referee agencies that verify safety and performance. Partial ISO 13485 Certification: Instead of waiting until an entire company, manufacturing line, and distribution network are fully operational to get audited, a company can undergo a certified audit specifically for a limited scope—such as its initial design and development processes. Feedback Call-to-Action We love hearing from our listeners! Did this episode change how you view early engagement with notified bodies? Do you have questions about implementing an eQMS or navigating partial ISO certification? Send your thoughts, topic requests, or guest recommendations directly to podcast@greenlight.guru . We read every message and respond personally to our community! Sponsors This episode of the Global Medical Device Podcast is brought to you by Greenlight Guru . Navigating the regulatory landscape requires a solid foundation built on quality and clear clinical evidence. Greenlight Guru provides the only dedicated eQMS (Quality Management System) and EDC (Electronic Data Capture) platform purpose-built for medical device and software-as-a-medical-device (SaMD) companies. Whether you are aiming for partial ISO 13485 certification, setting up your first design controls, or running clinical trials to collect vital regulatory breadcrumbs, Greenlight Guru helps you scale efficiently while keeping you audit-ready. Learn more about how Greenlight Guru's modern QMS and EDC solutions can accelerate your path to market at www.greenlight.guru .
November 17, 2021Episode 23617 min
A Special Glimpse into Medtronic's Recent Developments in Spine & Biologics Technology
Do you want to alleviate pain, restore health, and extend patients’ lifespan? Accelerate the transformation of the spine industry by making outcomes and technologies standardized and reproducible. In this episode of the Global Medical Device Podcast Jon Speer talks to Carlton Weatherby, Vice President and General Manager of Spine and Biologics at Medtronic. Listen to Carlton discuss recent developments in spine and biologics technology at Medtronic, a global healthcare technology leader tackling the most challenging health problems with innovative medical devices that transform patient lives. Some of the highlights of this episode include: The spine business is an untapped opportunity that can impact patients across the globe with technology solutions being developed by Medtronic. Would you rather live with back pain or have surgery? Basic spine surgery has advanced and improved, but there’s still a wide variability in the outcomes based on where patients live, training of the surgeons, and technologies used. Surgeons have more confidence and patients have more confidence in the surgeons as they identify a path to improve the patient’s condition, alleviate their pain, and perform a procedure to achieve greater outcomes. The golden age of medical devices due to innovation has made the regulatory environment more willing to collaborate. Regulators and the medical device industry try to help patients, but agree that there’s still room for improvement. Through partnership, acquisition, and organic development, Medtronic already has the assets and pieces to determine if surgery makes sense for patients. Medtronic has brought new products to the market to replace invasive spine surgery. An open procedure versus a minimally invasive surgery (MIS) takes more time and has more complications. Medtronic is bigger than most, and 80% of medical device companies have 50 or fewer employees. Startups dream about an acquisition. Carlton advises them to start with a clinical value proposition connected to a clinical need for customers. Memorable quotes from Carlton Weatherby: “Spine is very much an untapped opportunity in terms of the impact it can have on patients across the globe with technology solutions like the ones we’re developing.” “It’s still more of an art than a science and that’s where the opportunity lies.” “Areas of technology advancements that we’re making allow us to support our surgeons to instill the confidence that they have going into it and especially their patients.” “When you integrate new technologies, it’s not easy, especially if those technologies don’t talk together. That’s where an ecosystem truly becomes valuable.” Links: Carlton Weatherby on LinkedIn Medtronic Medtronic Spine Surgery Medtronic Minimally Invasive Spine Surgery (MIS+) Greenlight Guru Academy The Greenlight Guru True Quality Virtual Summit MedTech True Quality Stories Podcast Greenlight Guru YouTube Channel Greenlight Guru
November 23, 2022Episode 29143 min
Developing a Regulatory Strategy
What is a regulatory strategy? And for that matter, what do people sometimes think is a regulatory strategy but isn’t? Those are the questions that today’s guest, Mike Drues, discusses as he begins his conversation with host John Speer, founder of Greenlight Guru. Mike is President of Vascular Sciences, an education, training, and consulting company that offers many services to medical device, pharmaceutical, and biotechnology companies. Listen to the episode to learn how Mike thinks about competitive regulatory strategy, delays in complying with regulation, and reimbursement and regulatory strategy. Some of the highlights of this episode include: What regulatory strategy is and what it isn’t Why a good regulatory strategy is so important What competitive regulatory strategy is The mistake of focusing on only one company How the EU MDR is affecting regulatory strategy What causes delays in complying with regulations The industry record on post-market surveillance Reimbursement and regulatory strategy Memorable quotes from Mike Drues: “Let’s not forget my old friend, competitive regulatory strategy.” “It’s never too soon, in my opinion, to start thinking about regulatory strategy.” “As a general rule, we have done an abysmal job on post-market surveillance across the board.” “I consider this whole thing to be a poker game, in every sense of the word.” Links: Mike Drues LinkedIn How to Construct an Effective Regulatory Strategy Jon Speer LinkedIn Greenlight Guru Academy MedTech Excellence Community Greenlight Guru
Is this your show?
Claim this listing to keep it up to date, reach guests who want to pitch you, and manage bookings with Guestify.
